Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · March 23, 2022

Safety and Effectiveness of Long-Term IV Administration of Edaravone for ALS

JAMA Neurology


Additional Info

JAMA Neurology
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis
JAMA Neurol 2022 Feb 01;79(2)121-130, S Witzel, A Maier, R Steinbach, J Grosskreutz, JC Koch, A Sarikidi, S Petri, R Günther, J Wolf, A Hermann, J Prudlo, I Cordts, P Lingor, WN Löscher, Z Kohl, T Hagenacker, C Ruckes, B Koch, S Spittel, K Günther, S Michels, J Dorst, T Meyer, AC Ludolph

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading